These cases allege that the manufacturers promoted the medications as revolutionary weight-loss treatments while concealing severe risks such as gastroparesis, ileus, and bowel obstruction
Transduced cells were selected with 2 g/ml puromycin (Sigma-Aldrich, TR-1003-G).The DNA sequences of these shRNA genes were as follows: sh-NRF2-a forward: 5- CCG GCT TGC ATT AAT TCG GGA TAT ACT CGA GTA TAT CCC GAA TTA ATG CAA GTT TTT G-3 and reverse, 5- AAT TCA AAA ACT TGC ATT AAT TCG GGA TAT ACT CGA GTA TAT CCC GAA TTA ATG CAA G-3, sh-NRF2-b forward: 5-CCG GAG AGC AAG ATT TAG ATC ATT TCT CGA GAA ATG ATC TAA ATC TTG CTC TTT TTT G-3 and reverse, 5- AAT TCA AAA AAG AGC AAG ATT TAG ATC ATT TCT CGA GAA ATG ATC TAA ATC TTG CTC T-3, sh-C forward: 5- CCG GGC AAG CTG ACC CTG AAG TTC ACT CGA GTG AAC TTC AGG GTC AGC TTG CTT TTT G-3 and reverse, 5- AAT TCA AAA AGC AAG CTG ACC CTG AAG TTC ACT CGA GTG AAC TTC AGG GTC AGC TTG C-3
The report, published Thursday in the medical journal JAMA Ophthalmology, found that five out of 25,330 patients studied, or less than 0.02%, of those who took Ozempic and Wegovy, also known as GLP-1 drugs, developed non-arteritic anterior ischemic optic neuropathy, or NAION, a sudden loss of vision in one eye
EOPS 0F1 rats Male Sprague-Dawley EOPS 0F1 rats (IFFA CREDO, France) were used in this study
